Proximity to clinical onset influences motor and cognitive performance in presymptomatic Huntington disease gene carriers

Cognitive and Behavioral Neurology

Volumn 19, Issue 4, 2006, Pages 208-216

  Farrow, Maree ^a   Chua, Phyllis ^a   Churchyard, Andrew ^b   Bradshaw, John L ^a   Chiu, Edmond ^c   Georgiou Karistianis, Nellie ^a  

^a MONASH UNIVERSITY   (Australia)

^b Calvary Health Care Bethlehem ^*  (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Clinical onset; Huntington disease; Neuropsychology; Presymptomatic gene carriers

Indexed keywords

ADULT; ARTICLE; ASSOCIATION; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DECISION MAKING; FEMALE; HETEROZYGOSITY; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; MOVEMENT PERCEPTION; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PROBABILITY; REACTION TIME; RESPONSE TIME; SPATIAL ORIENTATION; SYMPTOM; TASK PERFORMANCE; VISUAL STIMULATION;

ADULT; CASE-CONTROL STUDIES; COGNITION; DISEASE PROGRESSION; FEMALE; HETEROZYGOTE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PREDICTIVE VALUE OF TESTS; REACTION TIME; REFERENCE VALUES; TIME FACTORS;

EID: 33845796508     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnn.0000213914.64772.b6     Document Type: Article

References (40)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-983.
2. Georgiou-Karistianis N, Smith E, Bradshaw JL, et al. Future directions in research with presymptomatic individuals carrying the gene for Huntington's disease. Brain Res Bull. 2003;59:331-338.
3. Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord. 2000;15:552-560.
4. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004;63:66-72.
5. Andrews TC, Weeks RA, Turjanski N, et al. Huntington's disease progression: PET and clinical observations. Brain. 1999;122:2353-2363.
6. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 1996;119:2085-2095.
7. Grafton ST, Mazziotta JC, Pahl JL, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol. 1992;49:1161-1167.
8. Hahn-Barma V, Deweer B, Durr A, et al. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J Neurol Neurosurg Psychiatry. 1998;64:172-177.
9. Kirkwood SC, Siemers E, Hodes ME, et al. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry. 2000;69:773-779.
10. Kirkwood SC, Siemers E, Stout JC, et al. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol. 1999;56:563-568.
11. Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998;121:1329-1341.
12. Lemiere J, Decruyenaere M, Evers-Kiebooms G, et al. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. Acta Neurol Scand. 2002;106:131-141.
13. Rosenberg NK, Sorensen SA, Christensen A. Neuropsychological characteristics of Huntington's disease carriers: a double blind study. J Med Genet. 1995;32:600-604.
14. Witjes-Ane MNW, Vegter-van der Vlis M, van Vugt JPP, et al. Cognitive and motor functioning in gene carriers for Huntington's disease: a baseline study. J Neuropsychiatry Clin Neurosci. 2003;15:7-16.
15. Blackmore L, Simpson SA, Crawford JR. Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease. J Med Genet. 1995;32:358-362.
16. Campodonico JR, Aylward E, Codori AM, et al. When does Huntington's disease begin? J Int Neuropsychol Soc. 1998;4:467-473.
17. Campodonico JR, Codori AM, Brandt J. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. J Neurol Neurosurg Psychiatry. 1996;61:621-624.
18. de Boo GM, Tibben A, Hermans J, et al. Memory and learning are not impaired in presymptomatic individuals with an increased risk of Huntington's disease. J Clin Exp Neuropsychol. 1999;21:831-836.
19. Giordani B, Berent S, Boivin MJ, et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol. 1995;52:59-64.
20. Paulsen JS, Zhao H, Stout JC, et al. Clinical markers for early disease in persons near onset of Huntington's disease. Neurology. 2001;57:658-662.
21. Snowden JS, Craufurd D, Thompson J, et al. Psychomotor, executive, and memory function in preclinical Huntington's disease. J Clin Exp Neuropsychol. 2002;24:133-145.
22. de Boo GM, Tibben A, Lanser JBK, et al. Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease. Arch Neurol. 1997;54:1353-1357.
23. Kirkwood SC, Siemers E, Bond C, et al. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch Neurol. 2000;57:1040-1044.
24. Siemers E, Foroud T, Bill DJ, et al. Motor changes in presymptomatic Huntington disease gene carriers. Arch Neurol. 1996;53:487-492.
25. de Boo GM, Tibben A, Hermans J, et al. Subtle involuntary movements are not reliable indicators of incipient Huntington's disease. Mov Disord. 1998;13:96-99.
26. Bradshaw JL, Phillips JG, Dennis C, et al. Initiation and execution of movement sequences in those suffering from and at-risk of developing Huntington's disease. J Clin Exp Neuropsychol. 1992;14:179-192.
27. Georgiou N, Bradshaw JL, Phillips JG, et al. The Simon effect and attention deficits in Gilles de la Tourette's syndrome and Huntington's disease. Brain. 1995;118:1305-1318.
28. Georgiou N, Bradshaw JL, Phillips JG, et al. Reliance on advance information and movement sequencing in Huntington's disease. Mov Disord. 1995;10:472-481.
29. Johnson KA, Cunnington R, Iansek R, et al. Movement-related potentials in Huntington's disease: movement preparation and execution. Exp Brain Res. 2001;138:492-499.
30. Simon JR. Reactions toward the source of stimulation. J Exp Psychol. 1969;81:174-176.
31. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65:267-277.
32. Huntington's Disease Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord. 1996;11:136-142.
33. Nelson HE. National Adult Reading Test (NART): Test Manual. Windsor: Nfer-Nelson; 1982.
34. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189-198.
35. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:53-63.
36. Cope MT, Georgiou N, Bradshaw JL, et al. Simon effect and attention in Parkinson's disease: a comparison with Huntington's disease and Tourette's syndrome. J Clin Exp Neuropsychol. 1996;18:276-290.
37. Williams SBK, Phillips JG, Bellgrove M, et al. Use of advance information in patients with schizophrenia. J Clin Exp Neuropsychol. 2000;22:472-482.
38. Bartenstein P, Weindl A, Spiegel S, et al. Central motor processing in Huntington's disease: a PET study. Brain. 1997;120:1553-1567.
39. Weeks RA, Ceballos-Baumann A, Piccini P, et al. Cortical control of movement in Huntington's disease: a PET activation study. Brain. 1997;120:1569-1578.
40. Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov Disord. 2001;16:407-423.